Impressive long-term response with pertuzumab and trastuzumab in HER2-positive breast cancer with brain metastasis
M Russillo, G Ferretti, A Vidiri, S Gasparro, F Cognetti… - in vivo, 2018 - iv.iiarjournals.org
This is a case report of a 40-year-old woman who, after conservative breast cancer
treatment, developed a HER2 positive solitary brain metastasis in the left temporal lobe …
treatment, developed a HER2 positive solitary brain metastasis in the left temporal lobe …
[HTML][HTML] Nearly complete response of brain metastases from HER2 overexpressing breast cancer with lapatinib and capecitabine after whole brain irradiation
E Oktay, Ö Yersal, N Meydan, M Sağıroğlu… - Case reports in …, 2013 - hindawi.com
Trastuzumab treatment does not prevent intracranial seeding and is largely ineffective for
established central nervous system metastasis in HER2 overexpressing breast cancer …
established central nervous system metastasis in HER2 overexpressing breast cancer …
HER2-positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab—a case report
DN Church, A Bahl, A Jones, CGA Price - Journal of neuro-oncology, 2006 - Springer
Brain metastases from metastatic breast cancer typically occur in 10–15% of patients and
are associated with survival of 3–6 months. Recent series have shown that women with …
are associated with survival of 3–6 months. Recent series have shown that women with …
[HTML][HTML] HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature …
M Chen, W Yu, B Cui, Y Yu, Z Ma - Frontiers in Oncology, 2023 - frontiersin.org
For HER2-positive metastatic breast cancer patients with the brain involved at initial
diagnosis, there was no standard regimen before 2022 when the HER2CLIMB trial …
diagnosis, there was no standard regimen before 2022 when the HER2CLIMB trial …
Pertuzumab, trastuzumab and docetaxel reduced the recurrence of brain metastasis from breast cancer: a case report
N Senda, A Yamaguchi, H Nishimura, T Shiozaki… - Breast cancer, 2016 - Springer
The CLEOPATRA trial reported the survival benefit of pertuzumab with trastuzumab plus
docetaxel in HER2-positive metastatic breast cancer patients. However, there are a few case …
docetaxel in HER2-positive metastatic breast cancer patients. However, there are a few case …
[HTML][HTML] Pertuzumab plus high-dose trastuzumab in patients with progressive brain metastases and HER2-positive metastatic breast cancer: primary analysis of a …
NU Lin, M Pegram, S Sahebjam, N Ibrahim… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Effective therapies are needed for the treatment of patients with human
epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC) with …
epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC) with …
[HTML][HTML] Brain metastases of Her2-positive breast cancer: A case of 34 months' remission with lapatinib plus capecitabine
A Mailliez, V Servent, J Bonneterre… - Case Reports in …, 2014 - karger.com
Abstract Breast tumors overexpressing Her2 (15% of breast cancers) are particularly at risk
for central nervous system parenchymal metastases. Whole-brain irradiation (WBI) is the …
for central nervous system parenchymal metastases. Whole-brain irradiation (WBI) is the …
Extended survival in women with brain metastases from HER2 overexpressing breast cancer
DN Church, R Modgil, S Guglani, A Bahl… - American journal of …, 2008 - journals.lww.com
Objectives: Brain metastases (BM) are a significant complication of metastatic breast cancer
(MBC). The high incidence of BM in HER2 overexpressing MBC is now well recognized …
(MBC). The high incidence of BM in HER2 overexpressing MBC is now well recognized …
[HTML][HTML] Metastatic brain tumors respond favorably to pyrotinib in a HER2-positive breast cancer following failure using trastuzumab
JH Yao, ZY Xie, M Li, ML Zhang, HF Ci… - American Journal of …, 2020 - ncbi.nlm.nih.gov
Abstract Treatment of breast cancer (BC) with overexpression of human epidermal growth
factor receptor 2 (HER2) has undergone a prosperous development with the advent of …
factor receptor 2 (HER2) has undergone a prosperous development with the advent of …
Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab
M Colozza, E Minenza, S Gori, D Fenocchio… - Cancer chemotherapy …, 2009 - Springer
Discussion Patients with HER-2 overexpressing metastatic breast cancer treated with
trastuzumab and chemotherapy develop central nervous system (CNS) metastases with an …
trastuzumab and chemotherapy develop central nervous system (CNS) metastases with an …